
Home » Janssen’s Fast-Tracked Nasal Spray Antidepressant Gets FDA Nod
Janssen’s Fast-Tracked Nasal Spray Antidepressant Gets FDA Nod

The FDA approved Johnson & Johnson’s Spravato (esketamine) nasal spray indicated for treatment-resistant depression in conjunction with an oral antidepressant.
The agency approved the drug through its fast-track and breakthrough therapy pathways, based on trial results that established the drug’s safety and efficacy and an endorsement from advisory committees.
The agency required a Risk Evaluation and Mitigation Strategy that restricts distribution to certified doctors’ offices and clinics.
Upcoming Events
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar
-
08Mar